Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Key Highlights
- ➤Boston Scientific (BSX) released Elutia’s full $8 million escrow holdback with no claims
- ➤Elutia (ELUT) says funding now extends through NXT-41x’s first launch year and into 2029
- ➤Elutia (ELUT) says no equity offering is needed to fund operations through commercialization
- ➤NXT-41x FDA clearance remains expected in the first half of 2027
- ➤Avenue Capital facility and SimpliDerm divestiture completed, delivering all three funding milestones
Expert Statements
Randy Mills, CEO of Elutia
“We said we would fund the Company through the NXT-41x launch, and in one quarter we did.”
Randy Mills, CEO of Elutia
“Every milestone we named has landed.”
Randy Mills, CEO of Elutia
“Full payment with no claims speaks to the quality of the products Elutia develops and builds.”
Randy Mills, CEO of Elutia
“With the balance sheet settled, we are laser-focused on taking this same technology into plastic and reconstructive surgery with NXT-41x, where surgical infection rates can reach 20%.”
* Boston Scientific released the full $8 million holdback on schedule and with no claims * Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture * The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88 million transaction. The Company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering.
Get started
Create a free account to read the full story.